PROGRAM &
POSTER LISTING
Join Our Mailing List
KEY DEADLINES
Abstract Submission: CLOSED
Scholarship Application Deadline: CLOSED
Standard Registration Deadline: CLOSED
Day 1 of the conference will begin at the following times
- Honolulu, HI, USA – 19:00, Saturday, 7 May 2022
- Phoenix, AZ, USA – 22:00, Saturday, 7 May 2022
- Baltimore, MD, USA – 01:00, Sunday, 8 May 2022
- Sao Paulo, Brazil – 02:00, Sunday, 8 May 2022
- London, UK – 06:00, Sunday, 8 May 2022
- Berlin, Germany – 07:00, Sunday, 8 May 2022
- Shanghai, China – 13:00, Sunday, 8 May 2022
- Tokyo, Japan – 14:00, Sunday, 8 May 2022
- Melbourne, Australia – 15:00, Sunday, 8 May 2022
- Auckland, New Zealand – 17:00, Sunday, 8 May 2022
To view the program in your local time, you can use the time zone converter tool here.
Please note that the program times are not the same for each day of the conference. Please check the other days to confirm starting time. The below times are listed in Australian Eastern Standard Time (Melbourne).
The program is in draft and is subject to change.
15:00 – 16:30
Opening Ceremony
Chairs: Damian Purcell and Fabiola Martin
Welcome to Country
Committee Welcome and IRVA President Introduction – Professor Damian Purcell and Dr Fabiola Martin
Australian Government Welcome – Hon Greg Hunt MP, Minister for Health and Aged Care
Women and HTLV – Invited speaker: Sandra do Valle, Brazil
20-year history of the Japanese HAM Patients Association – Invited speaker: Mr Shu Ishimoda, Smile Ribbon, Japan
My Story: Lack of HTLV-1 STI screening and referral pathways in Australia – Invited speaker: Ms Joanna Curteis, Patient Representative, Australia
Keynote Address – HTLV Research Successes, set-backs and strategies – Professor Graham Taylor, Imperial College, London UK
16:30 – 16:45
Break
16:45 – 17:47
2. Viral-host Interactions for HTLV-1 Transmission
Chairs: Helene Dutarte & Andrea Thoma-Kress
Viral Transmission
Invited speaker: Louis Mansky, Institute for Molecular Viroligy, USA
#18 Role of tetraspanins in HTLV-1 biofilm formation
Coline Arone, Université de Montpellier, France
#33 The helicase-like transcription factor inhibits infectious replication of human T-cell leukemia virus type 1.
Aurélie Beauvois, University of Liège, Belgium
#91 Transient expression of HTLV-1 Tax induces epigenetic alterations and mimics early T-cell activation
Daisuke Kurita, Kumamoto University, Japan
#71 HTLV-1 Retrovirus is Not Detected by Dendritic Cells but Alters their Response to a Restimulation
Auriane Carcone, Centre International de Recherche en Infectiologie, France
Panel Discussion and Q&A (15mins)
17:47 – 18:30
Break
18:30 – 19:32
3. Unravelling the molecular events in pathogenesis of HTLV-1
Chairs: Johan Van Weyenbergh & Anat Melamed
#111 Selective clonal persistence of HTLV-1 in vivo: radial chromatin organization, integration site and host transcription
Anat Melamed, Imperial College London, United Kingdom
#80 HTLV-1 INFECTED CELLS MODULATE TARGET CELLS AND VIRAL SPREAD VIA EXTRACELLULAR VESICLES
Fatah Kashanchi, George Mason University, USA
#99 In vivo antagonistic role of the Human T-Cell Leukemia Virus Type 1 regulatory proteins Tax and HBZ
Abdou Akkouche, American University Of Beirut, Lebanon
#67 HTLV-1 infection promotes excessive T cell activation and transformation into adult T cell leukemia / lymphoma
Benjy Jek Yang Tan, Kumamoto University, Japan
#50 Both HBZ Protein and mRNA upregulate TAp73 to promote the Warburg Effect in ATL cells
Kosuke Toyoda, Kumamoto University School of Medicine, Japan
Panel Discussion and Q&A (15mins)
19:32 – 19:45
Break
19:45 – 20:55
4. Who has HTLV-1 infection and where
Chairs: John Kaldor and Belinda Greenwood Smith
Global epidemiological aspects of HTLV-1 in the world with a focus on Africa, the largest HTLV-1 endemic area
Invited Speaker: Antoine Gessain, Pasteur France, France
#25 Prevalence and risk factors for human T-cell lymphotropic virus (HTLV) in blood donors in Brazil – a 10-year study (2007-2016).
Carolina Miranda, Universidade Federal De Minas Gerais, Brazil
#34 Prevalences Of HTLV, HIV And HBV In Patients Receiving Blood Transfusions In South Africa
Reynier Willemse, Sanbs, South Africa
#76 20 years of HTLV screening of blood donations in the UK
Ruth Wilkie, NHSBT, United Kingdom
#203 Retrospective study of Human T-cell Leukaemia Virus Type 1 & Adult T-cell Leukaemia/Lymphoma in Queensland, Australia.
Robert Gibb, Pathology Queensland, Australia
#61 Recent advances in HTLV-1 epidemiology.
Edward Murphy, UCSF and Vitalant Research Institute, United States
Panel Discussion and Q&A (15mins)
To view the program in your local time, you can use the time zone converter tool here.
Day 2 of the conference will begin at the following times
- Honolulu, HI, USA – 11:00, Sunday, 8 May 2022
- Phoenix, AZ, USA – 14:00, Sunday, 8 May 2022
- Baltimore, MD, USA – 17:00, Sunday, 8 May 2022
- Sao Paulo, Brazil – 18:00, Sunday, 8 May 2022
- London, UK – 22:00, Sunday, 8 May 2022
- Berlin, Germany – 23:00, Sunday, 8 May 2022
- Shanghai, China – 05:00, Monday, 9 May 2022
- Tokyo, Japan – 06:00, Monday, 9 May 2022
- Melbourne, Australia – 07:00, Monday, 9 May 2022
- Auckland, New Zealand – 09:00, Monday, 9 May 2022
Please note that the program times are not the same for each day of the conference. Please check the other days to confirm starting time.
The below times are listed in Australian Eastern Standard Time (Melbourne)
07:00 – 08:02
5. Animal models for HTLV
Chairs: Luc Willems and Patrick Green
#145 Bovine leukemia virus antisense transcription regulates viral replication, affects gene expression and directs host cell fate
Thomas Joris, Université de Liège, Belgium
#74 Single-cell NGS methods to track tumor precursor cells in HTLV-1 and BLV leukemia models
Jerome Wayet, Uliege, Belgium
#125 CD8+ cell depletion results in an increase in proviral loads in HTLV-1-infected cynomolgus macaques
Midori Nakamura-Hoshi, National Institute of Infectious Diseases, Japan
#72 Transient viral activation in HTLV-1-infected macaques treated with pomalidomide
Anna Gutowska, National Institutes Of Health, Vaccine Branch, United States
#24 The actin-bundling protein Fascin contributes to HTLV-1-induced lymphomagenesis in an ATLL xenograft mouse model
Andrea K. Thoma-Kress, Universitätsklinikum Erlangen, Virologisches Institut, Germany
#129 Combination antiretroviral therapy and MCL1 inhibition mitigate HTLV-1 infection in vivo
James Cooney, The Walter and Eliza Hall Institute, Australia
#75 Intragenic viral enhancer of HTLV-1 is dispensable for in vitro immortalization and in vivo persistence
Victoria Maksimova, The Ohio State University, United States
Panel Discussion and Q&A (25mins)
08:02 – 08:15
Break
08:15 – 09:17
6. How can testing improve clinical management?
Chairs: Philippa Hetzel and Junji Yamauchi
History of the HAM/TSP biomarker research
Invited Speaker: Yoshihisa Yamano, St. Marianna University School of Medicine, Japan
#126 Seroprevalence of neutralising antibodies in an HTLV-1c+ First Nations cohort from central Australia.
Samantha Gimley, The Peter Doherty Institute For Infection And Immunity, Australia
#153 Development of a pan-HTLV-1 Proviral Load Assay in Australia
Nick Vandegraaff, NRL/SVI, Australia
#83 Systemic cytokines and GlycA discriminate disease status and predict corticosteroid response in HTLV-1-associated neuroinflammation
Tatiane Assone, Fmusp, Brazil
#123 Flow cytometric assessment of T cell clonality for early detection of ATL: experience in the clinic
Aileen Rowan, Imperial College London, UK
Panel Discussion and Q&A (15mins)
09:17 – 09:45
Break
09:45 – 10:47
7. Clinical manifestations and biomarkers of disease during HTLV infection
Chairs: Yoshi Yamano and Mari Kannagi
Overall picture of genetic, epigenetic, and transcriptomic characteristics in ATL and HAM/TSP.
Invited Speaker: Makoto Yamagishi, The University of Tokyo, Tokyo, Japan
#136 Genome-wide association study of HAM/TSP susceptibility in Brazil reveals both immune and neural genetic links
Johan Van Weyenbergh, Ku Leuven, Belgium
#69 NGS quantification of viral clonal architecture identifies HTLV-1 asymptomatic carriers at high risk of progression to aggressive leukemia
Snehal Dilip Karpe, Laboratory of Viral Oncogenesis, Institut Jules Bordet, ULB & Unit of Animal Genomics, Belgium
#26 Role Of CTCF In Htlv-1 DNA Methylation, Gene Expression And Pathogenesis
Ancy Joseph, Washington University in Saint Louis, United States
#142 Analysis of neuroinflammatory biomarkers in HTLV-1-associated neurological disorders
Marzia Puccioni, Universidade Federal do Estado do Rio de Janeiro – UNIRIO, Brazil
Panel Discussion and Q&A (15mins)
10:47 – 11:00
Break
11:00 – 12:02
8. Key populations – Understanding and responding to HTLV in Vulnerable and First Nations Peoples
Chairs: Eduardo Gotuzzo and Ricardo Ishak
HTLV among vulnerable and indigenous communities in Brazil
Invited Speaker: Antonio Vallinoto, Universidade Federal do Pará, Brazil
HTLV-1 in Mahad/Iran: A Patient Perspective
#63 A qualitative study exploring perceptions to the human T cell leukaemia virus type 1 in Central Australia: Barriers to preventing transmission in a remote Aboriginal population
Fiona Fowler, Alice Salomon University of Applied Science, Australia
#133 Immune activation and dysfunction are defining characteristics of every HTLV-1c infection
Ashley Hirons, University Of Melbourne, Australia
#116 Determinants for the HTLV-1 maternal-to-child Transmission.
Gabriela Prates, Institute of Tropical Medicine, Brazil
Panel Discussion and Q&A (15mins)
12:02 – 12:15
Break
12:15 – 13:15
Sponsored Satellite Session – Cybernics Medical Innovation with Wearable Cyborg HAL
Chairs: Yoshi Yamano and Charles Bangham
Speaker: Yoshiyuki Sankai, President and CEO of CYBERDYNE Inc. Professor, Executive Research Director of Center for Cybernics Research, Director of F-MIRAI (R&D Center for Frontiers of MIRAI in Policy and Technology), University of Tsukuba, Japan
To view the program in your local time, you can use the time zone converter tool here.
Day 3 of the conference will begin at the following times
- Honolulu, HI, USA – 19:00, Monday, 9 May 2022
- Phoenix, AZ, USA – 22:00, Monday, 9 May 2022
- Baltimore, MD, USA – 01:00, Tuesday, 10 May 2022
- Sao Paulo, Brazil – 02:00, Tuesday, 10 May 2022
- London, UK – 06:00, Tuesday, 10 May 2022
- Berlin, Germany – 07:00, Tuesday, 10 May 2022
- Shanghai, China – 13:00, Tuesday, 10 May 2022
- Tokyo, Japan – 14:00, Tuesday, 10 May 2022
- Melbourne, Australia – 15:00, Tuesday, 10 May 2022
- Auckland, New Zealand – 17:00, Tuesday, 10 May 2022
Please note that the program times are not the same for each day of the conference. Please check the other days to confirm starting time.
The below times are listed in Australian Eastern Standard Time (Melbourne)
7:00 – 8:45
IRVA AGM
Welcome all existing and new IRVA members: Membership Secretary (FG) & President (FM)
Introductions to Board of Directors and Executive Committee members: Secretary (PJ)
President’s Report: President
Treasurer’s Report: Treasurer (AP)
Award Ceremony: Award Secretary (OH) & President
Closure: Secretary
15:00 – 16:02
9. HTLV-1 Community Perspective
Chairs: Fabiola Martin and Lloyd Einsendel
Invited Speaker Presentation
Achilea Bittencourt, Brazil
#113 HTLV Channel: Increasing awareness about HTLV
Carolina Rosadas, Imperial College London, United Kingdom
#156 The Epidemiology and clinical manifestations of the human T cell leukaemia virus Type 1C in remote Australian Aboriginal communities
Lloyd Einsiedel, Peter Doherty Institute, Australia
#49 Evidence of zoonotic and nosocomial transmission of htlv-1 in large survey in rural population of central Africa
Jil-Lea Ramassamy, Institute Pasteur, France
#97 The UK’s HTLV National Register: a unique cohort to inform disease progression
Katy Davison, Public Health England, United Kingdom
Panel Discussion and Q&A (15mins)
16:02 – 16:15
Break
16:15 – 17:17
10. Cutting-edge genomics approaches to improve our understanding of HTLV-1 associated disease
Chairs: Anne Van den Broeke and Franck Mortreux
Advanced sequencing technologies reveal new insights into oncogenic mechanism induced by HTLV-1
Invited Speaker: Dr Yorifumi Satou
#52 Chronological genome and single-cell epigenome/transcriptome integration characterizes the evolutionary process of adult T cell leukemia-lymphoma
Makoto Yamagashi, The University of Tokyo, Japan
#105 Dominant clones in high-risk HTLV-1 carriers have a genetic and transcriptomic profile closely resembling ATL clones
Sonia Wolf, Imperial College, United Kingdom
#102 Changes in 3D chromatin architecture upon NF-κB activation by TAX involve transcriptional and alternative splicing regulations
Paul Marie, Laboratory of Biology and Modelling of the Cell, France
#43 The dynamics and consequences of HTLV-1 Tax expression in naturally infected T-cell clones
Saumya Ramanayake, Imperial College London, United Kingdom
Panel Discussion and Q&A (15mins)
17:17 – 17:45
Break
17:45 – 19:02
11. Prevention Strategies
Chairs: Graham Taylor and Beatrice Macchi
Public health response to HTLV
Invited Speaker: Peter Figueroa, Jamaica
#54 Cellular proteins of the vesicular trafficking pathway regulate HTLV-1 retention in viral biofilm and infectivity of chronically infected cells
Helene Dutartre, Inserm. Ciri – Lyon, France
#37 Cryo-EM structures of the deltaretroviral intasome in complex with the host factor Protein Phosphatase 2A subunit B56γ and HIV integrase inhibitors.
Goedele N. Maertens, Imperial College London, United Kingdom
#109 HTLV seroprevalence among HIV PrEP users in England
Daniel Bradshaw, Uk Health Security Agency, United Kingdom
#85 Strengths, weaknesses, opportunities & threats for the implementation of public health policies on htlv-1 in Brazil: a swot analysis
Ricardo Ishak, Universidade Federal Do Para, Brazil
HTLV-1: Applying a global public health approach – Challenges and opportunities
Invited Speaker: Meg Doherty, World Health Organisation, Switzerland
Panel Discussion and Q&A (15mins)
19:02 – 19:15
Break
19:15 – 20:25
12. Clinical Trials (phase 1-IV)
Chairs: Lucy Cook and Masao Matsuoka
Novel approaches to future management of ATLL
Invited Speaker: Makoto Yoshimitsu, Kagoshima University Hospital, Japan
#39 First-in-human experience with hypomethylating agents and Venetoclax in Relapsed/Refractory North American Adult T-Cell Leukemia and Lymphoma patients (NA ATLL)
R. Alejandro Sica, Montefiore Einstein Center For Cancer Care, United States
#148 A Phase II Trial of Belinostat as Consolidation Therapy with Zidovudine for Adult T-Cell Leukemia-Lymphoma (ATLL): Interim Results
Juan Carlos Ramos, University of Miami- Sylvester Comprehensive Cancer Center, United States
#121 Efficacy and safety of brentuximab vedotin in adult T-cell leukemia/lymphoma
Nobuaki Nakano, Imamura General Hospital, Japan
#168 Beneficial impact of first-line mogamulizumab-containing chemotherapy in adult T-cell leukemia-lymphoma (ATL)
Hiro Tatetsu, Kumamoto University Hospital, Japan
#64 A randomized controlled trial on corticosteroid therapy for HTLV-1-associated myelopathy/tropical spastic paraparesis in Japan (HAMLET-P trial)
Junji Yamauchi, St. Marianna University, Japan
Panel Discussion and Q&A (15mins)
To view the program in your local time, you can use the time zone converter tool here.
Day 4 of the conference will begin at the following times
- Honolulu, HI, USA – 11:00, Tuesday, 10 May 2022
- Phoenix, AZ, USA – 14:00, Tuesday, 10 May 2022
- Baltimore, MD, USA – 17:00, Tuesday, 10 May 2022
- Sao Paulo, Brazil – 18:00, Tuesday, 10 May 2022
- London, UK – 22:00, Tuesday, 10 May 2022
- Berlin, Germany – 23:00, Tuesday, 10 May 2022
- Shanghai, China – 05:00, Wednesday, 11 May 2022
- Tokyo, Japan – 06:00, Wednesday, 11 May 2022
- Melbourne, Australia – 07:00, Wednesday, 11 May 2022
- Auckland, New Zealand – 09:00, Wednesday, 11 May 2022
The below times are listed in Australian Eastern Standard Time (Melbourne)
07:00 – 08:02
13. Non-Pharmacological/Behavioural Science
Chairs: Mrs Adine Adonis and Dr Mirna Biglione
Physiotherapy for Individuals with HAM/TSP
Invited Speaker: Katia Sá, Escola Bahiana de Medicina e Saúde Pública, Brazil
#38 Neurofunctional physical therapy protocol in patients with associated myelopathy to HTLV-1 (HAM).
Denise Goncalves, Ufmg, Brazil
#2 Prevalence and factors associated with depression and anxiety in people living with HTLV-1: A systematic review with meta-analysis and meta-regression
Lucca Souza, Federal University of Bahia, Brazil
#90 Multinational cross-sectional study on provision of HTLV care for blood donors with HTLV reactive serology
Fabiola Martin, University Of Queensland, Australia
#128 Defining research priorities for people living with HTLV-1 through patient/public involvement and engagement (PPIE) workshops
Adine Adonis, Imperial College Healthcare NHS Trust, United Kingdom
Panel Discussion and Q&A (15mins)
08:02 – 08:15
Break
08:15 – 09:17
14. Responding to co-infections
Chairs: Marzia Puccioni & Carolina Rosadas
Overview of HTLV-1 co-infections
Invited Speaker: Fernanda Grassi, Fiocruz, Brazil
#35 Human T-Lymphotropic virus type 1 and Human Immunodeficiency Virus co-infection in rural Gabon, Central Africa
Augustin Ghislain MOUINGA ONDEME, International Centre for Medical Research, Gabon
#202 COVID infection in patients with Human T-cell Leukemia Virus Type 1 (HTLV-1) infection, in Peru. Cases report
Eduardo Gotuzzo, Universidad Peruana Cayetano Heredia
#8 COVID-19 in individuals with HTLV-1 infection in Rio de Janeiro
Stephanie Monnerat, Universidade Federal Do Estado Do Rio De Janeiro, Brazil
#107 SARS-COV-2 Vaccination in people living with HTLV: vaccine hesitancy and antibody response
Divya Dhasmana, National Centre for Human Retrovirology, Imperial College Healthcare NHS Trust, London, United Kingdom
Panel Discussion and Q&A (15mins)
09:17 – 09:45
Break
09:45 – 10:47
15. Prospects for HTLV-1 preventive and therapeutic vaccines
Chairs: Genoveffa Franchini and Damian Purcell
A safe attenuated vaccine that protects from bovine leukemia virus infection in herds
Luc Willems, FNRS-ULiege, Belgium
#155 Preclinical evaluation of a subunit vaccine platform for HTLV-1
Keith Chappell, The University Of Queensland, Australia
#58 Potential anti-ATL therapeutic vaccine using short-term cultured autologous peripheral blood mononuclear cells: preclinical evidence in vitro and in vivo
Mari Kannagi, Department of Microbiology, Kansai Medical University, Japan
#46 In vivo and in vitro immunogenicity of novel MHC class I presented epitopes for a therapeutic peptide-based vaccine against HTLV-1.
Rashida Ginwala, Department of Medicine, Imperial College, United Kingdom
Panel Discussion
Luc Willems, Tetsuro Matano, Charles Bangham, Pooja Jain, Keith Chappell, Mari Kannagi, Rashida Ginwala, and Joanna Curteis
10:47 – 11:00
Break
11:00 – 12:30
16. Closing Plenary
Chairs: Fabiola Martin and Damian Purcell
Keynote Address – HIV vaccine efforts relevant the development of preventive HTLV-1 vaccines
Dr Genoveffa Franchini, National Institutes of Health, Vaccine Branch, USA
Patient Presentation – Invited Speaker: Joanna Curteis
Poster Awards
Closing Remarks and future announcements
Posters are listed by theme and alphabetical order of author.
Poster listing is subject to change.
Please click on the poster name to view the abstract.
Basic Science
William Arndt, University Of Minnesota – Twin Citites, United States
PO003 – Enriched cell pathways associated with dysregulated miRNAs expression by HTLV-2 infection
Andrea Corsi, University Of Verona, Italy
Peter Ellenberg, University of Melbourne, Australia
Yoshimi Enose-Akahata, Viral Immunology Section, NINDS, NIH, United States
Yoshimi Enose-Akahata, Viral Immunology Section, NINDS, NIH, United States
Kyle Ernzen, The Ohio State University, United States
Alisson Firmino, Bahiana School Of Medicine And Public Health, Brazil
PO010 – Immunogenic synthetic peptides: candidates for HTLV test of point of care development
Victor Folgosi, Laboratório De Dermatologia e Imunodeficiências, Instituto De Medicina Tropical De São Paulo / USP, Brazil
Greta Forlani, University Of Insubria, Italy
PO012 – Bio-id proximity mapping identifies cep63 as a centrosomal target of htlv-1 tax oncoprotein
Janelle Gauthier, CIRI, Centre International de Recherche en Infectiologie, France
Yago Gomes, Ioc/fiocruz, Brazil
Heather Hanson, University Of Minnesota, United States
Stefanie Heym, Institute Of Clinical And Molecular Virology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany
Rita Hleihel, American University Of Beirut, Lebanon
Md Belal Hossain, Kumamoto University, Japan
Dominic Sales, Drexel University, United States
Julie Joseph, Drexel University, United States
PO020 – 3’LTR occupancy by MEF-2C/Menin drives Adult T-cell Leukemia via HBZ
Pooja Jain, Drexel University, United States
Zach Cuba, George Mason University, United States
Sarah Al Sharif, George Mason University, United States
Laura M. Kemeter, Institute Of Clinical And Molecular Virology, Friedrich-alexander Universität Erlangen-nürnberg, Germany
PO026 – Temporal host transcription during spontaneous HTLV-1 proviral reactivation
Helen Kiik, Imperial College London, United Kingdom
Stephan Kohrt, Institute Of Clinical And Molecular Virology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany
PO028 – HBZ-related dysregulation of circular RNAs (circRNA) expression in ATLL
Julien Ladet, Laboratory of Biology and Modelling of the Cell, France
hsin-ching lin, Rutgers University, United States
PO030 – Investigating the Role of Base-Triples in the HTLV-1 pro-pol Frameshift Site Pseudoknot
Madison Maille, Loyola Marymount University, United States
Yair Mina, NINDS, NIH, United States
PO033 – Interactome and epigenetic functions of HTLV-1 Tax
Jun Mizuike, The University of Tokyo, Japan
PO034 – The retroviral transporter Rex hijacks the RNA helicase UPF1 in a CRM1 dependent manner.
Vincent Mocquet, ENS De Lyon, France
PO035 – KDR/VEGFR2 interacts with HTLV-1 Tax and prevents its autophagic degradation
Suchitra Mohanty, Penn State University College Of Medicine, United States
PO037 – Role of Monocytes, CTL and NK cells in primary HTLV-1 infection
Ramona Moles, National Institutes Of Health, Vaccine Branch, United States
Shingo Nakahata, Joint Research Center for Human Retrovirus Infection, Kagoshima University, Japan
PO039 – Whole genome sequence analysis of human T-cell leukemia virus type 1 in Peru
Shingo Nakahata, Joint Research Center for Human Retrovirus Infection, Kagoshima University, Japan
Nakano Nakano, Grad. Sch. Frontier Sci., The University of Tokyo, Japan
PO041 – Valemetostat, an EZH1/2 inhibitor, suppresses HTLV-1 infection in a humanized mouse model
Tokifumi Odaka, Kansai Medical University, Japan
PO043 – Analysis of EV Signatures from HAM/TSP Patient CSF
Michelle Pleet, NIH/NINDS, United States
PO044 – Modeling tumor-bone interactions in ATL with HTLV-1-infected peripheral blood cell lines
Nitin Pokhrel, Washington University in St Louis, United States
PO045 – Role of protein kinase cβ in adult t-cell leukemia lymphoma
Lee Ratner, Washington University, United States
Anne-sophie Reuter, Uliege, Belgium
PO047 – Construction and Characterization of two Chimeric HTLV-1AC infectious Molecular Clones
Sarkis Sarkis, National Institutes Of Health, Vaccine Branch, United States
Tomoo Sato, St. Marianna University School of Medicine, Japan
Annika Schnell, Institute Of Clinical And Molecular Virology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany
Mariam Shallak, University Of Insubria, Italy
PO051 – Characterizing the transfer of the mobile HTLV-1 accessory protein p8
Florian Simon, Universitätsklinikum Erlangen, Germany
PO052 – Gene targeted editing to disable the oncogenic retrovirus HTLV-1
Susan Smith, The Ohio State University, United States
Mary Soliman, Loyola Marymount University, United States
Miyu Sonoda, Departments Of Hematology, Rheumatology, And Infectious Diseases, Kumamoto University Hospital, Japan
PO056 – Precise excision of htlv-1 provirus with designer-recombinases
Andrea K. Thoma-Kress, Universitätsklinikum Erlangen, Virologisches Institut, Germany
Yu Wang, Department of Microbiology, Oita University Faculty of Medicine, Japan
Nora Willkomm, University Of Minnesota, United States
PO059 – HTLV-1 expression reduces local chromatin looping
Hiroko Yaguchi, Imperial College London, United Kingdom
Asami Yamada, Kumamoto University, Japan
Clinical Research - ATL
PO061 – Adult T-cell leukemia/lymphoma in French Guiana: Real-life data from 2009 to 2019
Karim Abdelmoumen, Université De La Réunion, France
Patricia Watber, Imperial College, United Kingdom
Hikaru SAKAMOTO, Department of Hematology, Nagasaki University Hospital, Japan
Ankit Shah, University Of Miami Miller School Of Medicine, United States
Atae Utsunomiya, Imamura General Hospital, Japan
Clinical Research - HAID (HTLV-1 associated inflammatory disease)
Adine Adonis, Imperial College Healthcare NHS Trust, United Kingdom
Tatiane Assone, Fmusp, Brazil
PO067 – By ignoring HTLV-1, is our understanding of the global burden of scabies only skin deep?
Beatrice Cockbain, Imperial College, United Kingdom
Anita Fletcher, National Institute Of Neurological Disease And Stroke/national Institues Of Health, United States
Naoki Iijima, Department of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Japan
Ana Carolina Marinho Monteiro Lima, Universidade Católica Do Salvador, Brazil
Ana Carolina Marinho Monteiro Lima, Universidade Católica Do Salvador, Brazil
PO073 – The imaging spectrum of HTLV-1 related neurological disease”
Cillian McNamara, Imperial College NHS Healthcare Trust, United Kingdom
PO074 – Immunopathogenic CSF TCR repertoire signatures in HAM/TSP
Satoshi Nozuma, Kagoshima University, Japan
PO075 – Case series: Pediatric T-cell Human Lymphotropic Virus type 1 and its clinical expression
Juan Rojas, Valle University, Colombia
PO076 – HTLV Elite Controllers: A diagnostic challenge and a learning opportunity
Carolina Rosadas, Imperial College London, United Kingdom
PO077 – Expanded Spectrum of Clinical Manifestations associated to HTLV-1 infection
Vicente Soriano, Universidad Internacional de La Rioja, Spain
Prevention, Epidemiology and Public Health
PO078 – the homeless population as the center of htlv control policies
Sarah Cassino, Unirio, Brazil
PO081 – prevalence of htlv-associated uveitis in patients of salvador. brazil
Daniele Ozores, Escola Bahiana De Medicina E Saúde Pública, Brazil
Pullukkutti Arachchige Dona Manori Piyumi Perera, National Std/aids Control Programme, Sri Lanka
José Guilherme Reis-Oliveira, Escola Bahiana De Medicina E Saúde Pública (EBMSP), Brazil
José Guilherme Reis-Oliveira, Escola Bahiana De Medicina E Saúde Pública (EBMSP), Brazil
Vicente Soriano, Universidad Internacional de La Rioja, Spain
Vicente Soriano, Universidad Internacional de La Rioja, Spain
PO088 – Self-perceived quality of life of asymptomatic htlv infected individuals
Ruth Wilkie, NHSBT, United Kingdom
Social Science & Community Forum
PO091- fake news in covid era and its impact beyond sars-cov-2: htlv-1 case
Carolina Rosadas, Imperial College London, United Kingdom